Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Inhibrx Biosciences, Inc. (INBX : NSDQ)

• Company Description    Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. Number of Employees: 161

• Price / Volume Information    Yesterday's Closing Price: $38.22 Daily Weekly Monthly 20 Day Moving Average: 146,163 shares Shares Outstanding: 14.48 (millions) Market Capitalization: $553.63 (millions) Beta: 0.51 52 Week High: $39.27 52 Week Low: $10.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 40.93% 40.06% 12 Week 55.56% 47.58% Year To Date 148.18% 116.73%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11025 N. TORREY PINES ROAD SUITE 140 - LA JOLLA,CA 92037 USA ph: 858-795-4220 fax: - ir@inhibrx.com https://inhibrx.com

• General Corporate Information    Officers Mark P. Lappe - Chief Executive Officer and Chairman Kelly D. Deck - Chief Financial Officer Jon Faiz Kayyem - Director Douglas G. Forsyth - Director Kimberly Manhard - Director Peer Information Inhibrx Biosciences, Inc. (CORR.) Inhibrx Biosciences, Inc. (RSPI) Inhibrx Biosciences, Inc. (CGXP) Inhibrx Biosciences, Inc. (BGEN) Inhibrx Biosciences, Inc. (GTBP) Inhibrx Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45720N103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 14.48 Most Recent Split Date: (:1) Beta: 0.51 Market Capitalization: $553.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.07 Price/Cash Flow: 0.33 Price / Sales: - EPS Growth vs. Year Ago Period: -101.47% vs. Previous Quarter: 33.93% Sales Growth vs. Year Ago Period: 1,200.00% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -137.83 03/31/25 - -85.12 ROA 09/30/25 - - 06/30/25 - -76.31 03/31/25 - -58.90 Current Ratio 09/30/25 - - 06/30/25 - 4.98 03/31/25 - 5.12 Quick Ratio 09/30/25 - - 06/30/25 - 4.98 03/31/25 - 5.12 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -11,692.29 03/31/25 - 861,486.44 Book Value 09/30/25 - - 06/30/25 - 4.74 03/31/25 - 6.52 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 1.45 03/31/25 - 1.04 Debt-to-Capital 09/30/25 - - 06/30/25 - 59.15 03/31/25 - 51.09

Powered by Zacks Investment Research ©